Mourabit Halima, Author at MediaMedic

Real-World Evidence Supports Trastuzumab Deruxtecan in HER2+ Breast Cancer with Brain Metastases

By Mourabit Halima 2025.04.08

In a multicenter observational study across 12 Italian oncology units, Dr. Alessandra Fabi and colleagues evaluated the real-life effectiveness of Trastuzumab Deruxtecan (T-DXd) in 39 patients with HER2-positive breast cancer…

Epigenetics in Breast Cancer: The Rise of Precision Medicine

By Mourabit Halima 2025.04.07

Published in Breast Cancer (Springer) in June 2024,Sujata Purja, Dung Thuy Nguyen, and Eunyong Kim provide a comprehensive analysis of the evolving landscape of breast cancer epigenetics, emphasizing the therapeutic…

Real-World Evidence on the Hugo™ RAS System in Urologic Surgery: Global Data from 917 Patients

By Mourabit Halima 2025.04.07

At EAU25, Professor Alexander Mottrie presented the latest real-world findings from one of the largest prospective series evaluating the Hugo™ Robotic-Assisted Surgery (RAS) System in urology. This international study, conducted…

APPEAL Trial: Landmark International RCT Shows Ciprofloxacin Lowers Post-SWL Infection Risk

By Mourabit Halima 2025.04.06

Presented by Dr. Kari Tikkinen and team at EAU25, the APPEAL trial is the largest randomized controlled study to date evaluating the role of antimicrobial prophylaxis during shock wave lithotripsy…

BOND-003: Intravesical Cretostimogene Shows Durable Responses in High-Risk BCG-Unresponsive NMIBC

By Mourabit Halima 2025.04.06

Presented by Dr. Trinity Bivalacqua at EAU25, the BOND-003 Phase 3 trial showcases updated data on intravesical cretostimogene grenadenorepvec, an innovative oncolytic immunotherapy for patients with high-risk BCG-unresponsive non–muscle invasive…

Dr. Sarah Psutka MD MSc presents interim results from the SunRISe-4 trial at EAU25

By Mourabit Halima 2025.04.04

At the EAU25 Congress, Dr. Sarah Psutka MD MSc shared promising data from the SunRISe-4 trial evaluating neoadjuvant TAR-200 plus cetrelimab in patients with muscle-invasive bladder cancer (MIBC) who are…

EAU25 | Dr. Dr. med. Yannic Volz Presents the PRACTICE Study: Can Prehabilitation Improve Radical Cystectomy Outcomes?

By Mourabit Halima 2025.04.03

At #EAU25, Dr. Yannic Volz (Ludwig-Maximilians-Universität München) introduced early insights from the ongoing PRACTICE trial (NCT06806059), a randomized, single-blinded study assessing the impact of structured physical activity before radical cystectomy…

EAU25 | Dr. Seth Lerner Shares First-in-Human Results on Bel-sar (AU-011) in NMIBC

By Mourabit Halima 2025.04.03

At #EAU25, Dr. Seth Lerner (Baylor College of Medicine) presented early findings from a Phase 1 study (NCT05483868) evaluating Bel-sar (AU-011)—a novel virus-like drug conjugate (VDC) for non-muscle invasive bladder…

EAU25 | Dr. Nikhil Mayor Presents NeuroSAFE PROOF Trial: Advancing Nerve-Sparing in Prostate Cancer Surgery

By Mourabit Halima 2025.04.01

At #EAU25, Dr.Nikhil Mayor (Imperial College London) presented results from the NeuroSAFE PROOF trial (NCT03317990)—the first randomized, controlled, single-blinded study comparing NeuroSAFE-guided versus standard robot-assisted radical prostatectomy (RARP) in localized…

EAU25 | PERSIAN Trial: Can SBRT Enhance Systemic Therapy in Oligometastatic mHSPC?

By Mourabit Halima 2025.04.01

At #EAU25, Dr. Giulio Francolini and colleagues presented early results from the ongoing PERSIAN trial (NCT03449719) a randomized phase II study investigating the addition of stereotactic body radiotherapy (SBRT) to…